Enhancement of anti-tumour immunity in syngeneic mice after MHC class II gene transfection

British Journal of Cancer

Volumn 74, Issue 2, 1996, Pages 258-263

  Mongini, C ^a   Sanchez Lockhart M ^a   Waldner, C I ^a   Alvarez, E M C ^a   Gravisaco, M J ^a   Roig, M I ^a   Hajos, S E ^a  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

Anti tumour immunity; Gene transfection; Murine leukaemia

Indexed keywords

MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2;

ANIMAL CELL; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; DNA SEQUENCE; HISTOCOMPATIBILITY GENE; LEUKEMIA CELL; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SOUTHERN BLOTTING;

EID: 0030055507     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1996.348     Document Type: Article

References (35)

1. ALVAREZ E, MONGINI C, WALDNER C, FERNÁNDEZ T, NAOR D AND HAJOS S. (1989). The interrelationships between spontaneous murine leukaemia LB and the immune system. LB is a non-immunogenic tumour in its syngeneic host. J. Exp. Clin. Res., 8, 181-192.
2. BASKAR S, AZARENKO V, GARCIA MARSHALL E, HUGHES E AND OSTRAND-ROSEMBERG S. (1994). MHC class II-transfected tumour cells induce long-term tumour-specific immunity in autologous mice. Cell. Immunol., 155, 123-133.
3. BASKAR S, GLIMCHER L, NABAVI N, JONES RT AND OSTRAND-ROSEMBERG S. (1995). Major histocompatibility complex class II+ B7-1+ tumour cells are potent vaccines for stimulating tumour rejection in tumour-bearing mice. J. Exp. Med., 181, 619-629.
4. BOTTAZO GF, DEAN BM, MCNALLY JM, MACKAY EH, SWIFT PG AND GAMBLE DR. (1985). In situ characterization of autoimmune phenomena and expression of HLA molecules in the pancreas in diabetic insulinitis. N. Engl. J. Med., 313, 353-360.
5. BURNET FM. (1970). The concept of immunological surveillance. Prog. Exp. Tumour. Res., 13, 1-27.
6. COLIGAN JE, MARGULLES D, SHEVACH EM AND STROBER W. (1992). In vitro assays for mouse B and T function. In Current Protocols in Immunology, pp. 3.11,4-7 Greene Publishing & Wiley Interscience: New York.
7. DADMARZ R, SGAGIAS MK, ROSENBERG SA AND SCHWARTZEN-TRUBER DJ. (1995). CD4+ T lymphocytes infiltrating human breast cancer recognize autologous tumour in an MHC class-II restricted fashion. Cancer Immunol. Immunother., 40, 1-9.
8. DORMAN I. (1989). Cationic liposome-mediant transfection of suspension cell cultures. FOCUS, 1, 37.
9. FEARON ER, PARDOLL DM, ITAYA T, GOLUMBEK P, LEVITSKY HI, SIMONS JW, KARASUYAMA H, VOGELSTEIN B AND FROST P. (1990). Interleukin-2 production by tumour cells bypasses T helper function in the generation of an anti-tumour response. Cell, 60, 397-403.
10. FUJI H AND IRIBE H. (1986). Clonal variation in tumorigenicity of L1210 lymphoma cells: non tumourigenic variants with enhanced expression of tumour associated antigens and Ia antigens. Cancer Res., 46, 5541-5547.
11. GLIMCHER LH AND KARA CJ. (1992). Sequences and factors: a guide to MHC class-II transcription. Annu. Rev. Immunol., 10, 13-49.
12. GOLUMBEK P, LAZENBY AJ, LEVITSKY HI, JAFFEE LM, KARASUYAMA H, BAKER M AND PARDOLL D. (1991). Treatment of established renal cancer by tumour cells engineered to secrete interleukin-4. Science, 254, 713-716.
13. GROSS-BELLARD M, ODUDET P AND CHAMBON P. (1973). Isolation of high-molecular weight DNA from mammalian cells. Eur. J. Biochem., 36, 32-38.
14. HAMMERLING GJ, KLAR D, PULM W, MOMBURG F AND MOLDENHAUER G. (1987). The influence of major histocompatibility class I antigens on tumour growth and metastasis. Biochim. Biophys. Acta, 907, 245-251.
15. IOANNIDES CG AND WHITESIDE TL. (1983). T cell recognition of human tumours: implication for molecular immunotherapy of cancer. Clin. Immunol. Immunopathol., 66, 91-106.
16. JACOBSON S, RICHERT JR, BIDDISON W, SATINSKY A, HARTZMAN RJ AND McFARLAND HF. (1984). Measles virus-specific T4+ human cytotoxic T cells clones are restricted by class II HLA antigens. J. Immunol., 133, 754-757.
17. JAMES RFL, EDWARDS S, HUI KM, BASSET PD AND GROSVELD F. (1991). The effect of class II gene transfection on the tumorigenicity of the H-2K-negative mouse leukaemia cell line K36.16. Immunology, 72, 213-228.
18. KAPPLER LW, SKIDMORE B, WHITE J AND MARRAK P. (1981). Antigen-inducible, H-2-restricted, IL-2-producing T cell hybridomas. Lack of independent antigen and H-2 recognition. J. Exp. Med., 153, 1198-1214.
19. KEM DE, KIAMET JP, JENSEN MCV AND GREENBERG M. (1986). Requirement for recognition of class II molecules and processed tumour antigen for optimal generation of syngeneic tumour-specific class I-restricted CTL. J. Immunol., 136, 4303-4310.
20. LINDAHL P, LEARY P AND GRESSER I. (1974). Enhancement of the expression of histocompatibility antigens of mouse lymphoid cells by interferon in vitro. Eur. J. Immunol., 4, 779-784.
21. LONDEI M, LAMB JR, BOTAZZO G AND FELDMAN M. (1984). Epithelial cells expressing aberrant MHC class II determinants can present antigen to cloned human T cells. Nature, 312, 639-641.
22. LUGASI H, HAJOS S, MURPHY JR, STROM TB, NICHOLS J, PEÑARROJA C AND NAOR D. (1990). Murine spontaneous T-cell leukaemia constitutively expressing IL-2R: A model for human T cell malignancies expressing IL-2R. Int. J. Cancer, 45, 163-167.
23. d class I MHC determinants in the context of class II MHC molecules. J. Immunol., 147, 2868-2874.
24. MONGINI C, WALDNER C, ROIG I AND HAJOS S. (1991). Murine T cell leukaemia line in suspension culture. In Vitro Cell. Dev. Biol., 27, 523-524.
25. MONGINI C, WALDNER CI, ALVAREZ E, ROIG MI, SÁNCHEZ LOCKHART M, GRAVISACO MJ AND HAJOS SE. (1995). Induction of anti-tumour immunity in syngeneic mice by a leukaemic cell line. Scand. J. Immunol., 41, 298-304.
26. MOUDGIL K AND SERCARZ EE. (1994). Can antitumour immune responses discriminate between self and nonself? Immunol. Today, 15, 353-355.
27. OSTRAND-ROSEMBERG S, THAKUR A AND CLEMENTS V. (1990). Rejection of mouse sarcoma cells after transfection of MHC class II genes. J. Immunol., 144, 4068-4071.
28. PARDOLL, DM. (1993). Cancer vaccines. Immunol. Today, 14, 310-316.
29. PETO R, PIKE MC, ARMITAGE P, BRESLOW NE, COX DR, HOWARD SV, MANTIEL N, McPHETERSON K, PETO J AND SMITH P. (1977). Design and analysis of randomized clinical trials requiring prolonged observation of each patient. Br. J. Cancer, 35, 1-39.
30. PIPPIN BA, ROSENSTEIN M, JACOB WF, CHIANG Y AND LOTZE MT. (1994). Local IL-4 delivery enhances immune reactivity to murine tumours: gene therapy in combination with IL-2. Cancer Gene Ther., 1, 1-7.
31. RUGGIERO RA, BUSTUOABAD OD, BONFIL RD, MEISS RP AND PASQUALINI CD. (1984). Concomitant immunity in murine tumours of non-detectable immunogenicity. Br. J. Cancer, 51, 1-10.
32. SAMBROOK J, FRITSCH EF AND MANIATIS T. (1989). Analysis and cloning of eukaryotic genomic DNA. In Molecular Cloning: a Laboratory Manual, 2nd Ed, pp. 9-34. Cold Spring Harbor Laboratory Press: New York.
33. STEINMETZ M, MINARD K, HORVATH S, MCNICHOLAS J, SRELINGER J, WAKE C, LONG E, MACH B AND HOOD L. (1982). A molecular map of the immune response region from the major histocompatibility complex of the mouse. Nature, 300, 35-42.
34. STEINMETZ M, MALISSEN M, HOOD L, ÖRN A, MAKI RA, DASTOORMIKOO GR, STEPHAN D, GIBB E AND ROMANIUK R. (1984). Tracks of high or low sequences divergencies in the mouse major histocompatibility complex. EMBO J., 3, 2995-3003.
35. TANAKA T, YOSHIOKA T, BIEBERICH C AND JAY G. (1988). Role of the MHC class I antigens in tumour growth and metastasis. Annu. Rev. Immunol., 6B, 359-380.